Tekmira Pharmaceuticals Corp (TKMR) 10.83 $TKMR
Global Gastric Cancer Drugs Market 2016-2020 - Market Segmentation By Molecule Type, Route of Administration & Lines of Chemotherapy
M2 - Tue Jan 05, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/dd7vml/global_gastric) has announced the addition of the "Global Gastric Cancer Drugs Market 2016-2020" report to their offering. The report predicts the global gastric cancer drugs market to grow rapidly at a CAGR of approximately 8% during the forecast period. The presence of huge unmet needs in the market is expected to result in this market's healthy growth during the forecast period. The presence of this high-unmet medical need will lead to an increased R&D of safe and effective drugs, which in turn will spur market growth during the estimated period. The recent increase in the prevalence of gastric cancer due to lifestyle changes is expected to drive market growth. The sedentary lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity are envisaged to result in the increased incidence of gastric cancer. This study estimates the APAC region to account for the highest market share during the forecast period. Much of this region's growth can be attributed to the increasing demand for better healthcare infrastructure, which results in its massive market share of nearly 48% during the forecast period. The global gastric cancer drugs market is growing rapidly owing to the high proportion of individuals with gastric cancer and the presence of a strong drug pipeline. To gain traction in this market, the vendors are manufacturing and marketing gastric cancer drugs that exhibit a high safety and efficacy profile, this helps the vendors to gain a competitive edge over their peers. Companies Mentioned: - Hoffmann-La Roche - Eli-lilly - Sanofi - Otsuka Holdings - Novartis - Amgen - Boston Biomedical - AROG Pharmaceuticals - ARIAD Pharmaceuticals - Roche - Merck - Eli Lilly - AB Science - Galena Biopharma - AstraZeneca - Taiho Oncology - Samumed - Ipsen Biopharmaceuticals - Eddingpharm - Tekmira Pharmaceuticals - Bristol-Myers Squibb - Gilead Sciences - ASLAN Pharmaceuticals - Five Prime - Array Biopharma - BIND Therapeutics - Boehringer Ingelheim - Daiichi-Sankyo - Bayer HealthCare - Celgene. Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Disease overview PART 06: Pipeline portfolio PART 07: Market landscape PART 08: Market segmentation by molecule type PART 09: Market segmentation by route of administration PART 10: Market segmentation by lines of chemotherapy PART 11: Geographical segmentation PART 12: Market drivers PART 13: Impact of drivers PART 14: Market challenges PART 15: Impact of drivers and challenges PART 16: Market trends PART 17: Vendor landscape PART 18: Key vendor analysis For more information visit http://www.researchandmarkets.com/research/dd...al_gastric
GILD: 81.68 (-1.69), MRK: 56.72 (-0.96), TKMR: 10.83 (+0.58), AMGN: 147.83 (-4.44), GALE: 2.07 (-0.08), LLY: 74.45 (+0.51), BIND: 0.40 (unch), BMY: 71.48 (-1.16), ARIA: 7.35 (-0.19), NVS: 78.41 (-2.26), CELGZ: 1.54 (+0.09)
Non-Hodgkin Lymphoma - Pipeline Review, H1 2015
M2 - Thu Sep 10, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njqxnc/nonhodgkin) has announced the addition of the "Non-Hodgkin Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 110 companies mentioned in this comprehensive report: - AB Science - AbbVie - BioAtla, - Biogenomics - Calimmune - Calithera Biosciences - Dicerna Pharmaceuticals - Eisai Co. - Eli Lilly and Company - F. Hoffmann-La Roche - Formula Pharmaceuticals - Galderma - Gamida Cell - Hetero Drugs - Hospira - iDD biotech - Immune Design - Johnson & Johnson - Juno Therapeutics - Kainos Medicine - Karyopharm Therapeutics - MedImmune - Merck & Co. - Nordic Nanovector - Novartis - OncoSec Medical - Onxeo - Pfizer - Pharma Mar - Richter Gedeon - Sanofi - Tekmira Pharmaceuticals - Vivia Biotech - Xenetic Biosciences - Zymeworks For more information, including full list of companies mentioned, please visit http://www.researchandmarkets.com/research/njqxnc/nonhodgkin
IMDZ: 8.07 (-0.23), DRNA: 3.09 (-0.20), TKMR: 10.83 (+0.58), LLY: 74.45 (+0.51), JNJ: 116.38 (-1.00), MRK: 56.72 (-0.96), CALA: 4.02 (-0.19), ONCS: 1.58 (-0.02), JUNO: 41.95 (-1.75), KPTI: 7.77 (-0.26), NVS: 78.41 (-2.26)
High Triglyceridemia - Pipeline Review, H2 2015
M2 - Tue Sep 08, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k6prfz/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - BASF SE - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Essentialis, Inc. - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Michigan Life Therapeutics, LLC - Novartis AG - Pharmena SA - Tekmira Pharmaceuticals Corp. - Thetis Pharmaceuticals LLC For more information visit http://www.researchandmarkets.com/research/k6prfz/high
AGN: 228.48 (-5.03), ACST: 1.50 (+0.04), ISIS: 57.56 (-0.28), AZN: 28.20 (-1.09), TKMR: 10.83 (+0.58), CBAY: 1.72 (-0.07), NVS: 78.41 (-2.26)
InMed Appoints Paul Brennan to the Board of Directors
Marketwired - Tue Aug 25, 4:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company"
(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Paul Brennan to the Company's Board of Directors. Mr. Brennan brings more than 25 years of experience in building, leading and advising top-performing pharmaceutical and biotechnology companies in Europe, Canada and the United States.
ABUS: 3.45 (-0.09), TKMR: 10.83 (+0.58)
Arbutus Biopharma (NASDAQ: ABUS) Finalizes Corporate Name Change From Tekmira Pharmaceuticals
GlobeNewswire - Mon Aug 03, 4:45AM CDT
Arbutus Biopharma Corporation (NASDAQ:ABUS) today announced finalization of its corporate name change from Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR). Arbutus Biopharma ("Arbutus" is an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV). Arbutus will begin trading under the new ticker symbol ABUS on the NASDAQ today. The company has also received a new CUSIP number (03879J100) for its common stock.
ABUS: 3.45 (-0.09), TKMR: 10.83 (+0.58)
US Blood Cancer Drug Market & Pipeline Analysis 2015
M2 - Wed Jul 22, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp4cd3/us_blood_cancer) has announced the addition of the "US Blood Cancer Drug Market & Pipeline Analysis 2015" report to their offering. Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs. Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market. Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase. "US Blood Cancer Drug Market & Pipeline Analysis 2015" Report Highlights: - Blood Cancer Incidence & Prevalence - Blood Cancer Drug Market Overview - Blood Cancer Drug Market Dynamics - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs - Majority Drugs in Phase-I Clinical Trials: 128 Drugs - Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis - Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs Key Topics Covered: 1. US Blood Cancer Incidence & Prevalence 2. US Blood Cancer Drug Market Overview 3. US Blood Cancer Drug Market Dynamics 4. US Blood Cancer Drug Market Future Prospects 5. Mechanism of Blood Cancer Therapeutics 6. Leukemia Drug Clinical Pipeline by Company & Phase 7. Marketed Leukemia Drug Clinical Insight 8. Lymphoma Drug Clinical Pipeline by Company & Phase 9. Marketed Lymphoma Drug Clinical Insight 10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase 11. Marketed Multiple Myeloma Drug Clinical Insight 12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase 13. Marketed Multiple Blood Cancer Drug Clinical Insight 14. Competitive Landscape - ARIAD Pharmaceuticals - Actelion Pharmaceuticals - Amgen - Astellas Pharma - Baxter BioScience - Bayer HealthCare Pharmaceuticals Inc. - Biogen Idec - Bristol-Myers Squibb - CASI Pharmaceuticals - Celera Genomics Group - Celgene Corporation - Eisai Co Ltd - Genmab - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Millennium Pharmaceuticals - Nova Laboratories - Novartis - Onxeo SA - Onyx Pharmaceuticals - Otsuka Pharmaceutical - Pfizer - Roche - SRI International - Scripps Clinic - Seattle Genetics - Southern Research Institute - Tekmira Pharmaceuticals Corporation - Teva Pharmaceutical Industries - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/hp...ood_cancer
BIIB: 233.49 (-5.13), TKMR: 10.83 (+0.58), AMGN: 147.83 (-4.44), GSK: 40.97 (-1.59), BMY: 71.48 (-1.16), CASI: 1.21 (-0.02), JNJ: 116.37 (-1.01), GILD: 81.68 (-1.69), TEVA: 50.73 (-0.64), ARIA: 7.35 (-0.19), NVS: 78.41 (-2.26), CELGZ: 1.54 (+0.09)
Tekmira suspends work on Ebola drug, will change name
AP - Mon Jul 20, 3:21PM CDT
NEW YORK (AP) — One of the companies that had been studying a potential treatment for the Ebola virus said Monday it will suspend its research on Ebola drugs and change its name.
AGN: 228.48 (-5.03), INO: 9.42 (-0.43), TKMR: 10.83 (+0.58), GSK: 40.97 (-1.59), TKM.TO: 22.97 (+0.52)
The Single Greatest Mistake You Can Make When Investing in Biotech
Sean Williams, The Motley Fool - Motley Fool - Sun Jul 12, 1:02PM CDT
Source: Food and Drug Administration via Facebook Investing in the biotech sector since the Great Recession must be somewhat reminiscent of the pre-dot-com bubble for traders. These days it seems as if you threw a dart at the newspaper you could...
NVAX: 6.66 (-0.25), TKMR: 10.83 (+0.58)
Tekmira says Ebola drug unlikely to work in study
AP - Fri Jun 19, 5:02PM CDT
NEW YORK (AP) — Drugmaker Tekmira said Friday that an experimental treatment for a strain of Ebola will probably fail in a clinical trial.
TKMR: 10.83 (+0.58), TKM.TO: 22.97 (+0.52)
Tekmira Provides Update on TKM-Ebola-Guinea
GlobeNewswire - Fri Jun 19, 7:00AM CDT
Phase 2 clinical trial enrollment closed
TKMR: 10.83 (+0.58)
Tekmira to Present at JMP Securities Life Sciences Conference
GlobeNewswire - Thu Jun 18, 7:00AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced that Dr. Mark J. Murray, Tekmira's President and CEO, will present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 24, 2015 at 11.00am - 11.30am (PT) / 2.00 - 2.30pm (ET) in New York.
TKMR: 10.83 (+0.58)
Dementia drug developer Axovant climbs after $315M IPO
AP - Thu Jun 11, 6:32PM CDT
NEW YORK (AP) — Shares of Axovant Sciences nearly doubled in value after the dementia drug developer said its initial public offering raised $315 million, more than Axovant had expected.
TKMR: 10.83 (+0.58), GSK: 40.97 (-1.59), TKM.TO: 22.97 (+0.52)
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9bg7xn/adrenocortical) has announced the addition of the "Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Marathon Pharmaceuticals, LLC - Merck KGaA - Neotropix, Inc. - Orphagen Pharmaceuticals, Inc. - Pfizer Inc. - Tekmira Pharmaceuticals Corp. Drug Profiles - ATR-101 - avelumab - axitinib - MP-110 - NTX-010 - Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - TKM-PLK1 For more information visit http://www.researchandmarkets.com/research/9b...nocortical
PFE: 34.25 (-0.34), TKMR: 10.83 (+0.58)
Global Gastric Cancer Drugs Market 2016-2020 - Market Segmentation By Molecule Type, Route of Administration & Lines of Chemotherapy
M2 - Tue Jan 05, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/dd7vml/global_gastric) has announced the addition of the "Global Gastric Cancer Drugs Market 2016-2020" report to their offering. The report predicts the global gastric cancer drugs market to grow rapidly at a CAGR of approximately 8% during the forecast period. The presence of huge unmet needs in the market is expected to result in this market's healthy growth during the forecast period. The presence of this high-unmet medical need will lead to an increased R&D of safe and effective drugs, which in turn will spur market growth during the estimated period. The recent increase in the prevalence of gastric cancer due to lifestyle changes is expected to drive market growth. The sedentary lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity are envisaged to result in the increased incidence of gastric cancer. This study estimates the APAC region to account for the highest market share during the forecast period. Much of this region's growth can be attributed to the increasing demand for better healthcare infrastructure, which results in its massive market share of nearly 48% during the forecast period. The global gastric cancer drugs market is growing rapidly owing to the high proportion of individuals with gastric cancer and the presence of a strong drug pipeline. To gain traction in this market, the vendors are manufacturing and marketing gastric cancer drugs that exhibit a high safety and efficacy profile, this helps the vendors to gain a competitive edge over their peers. Companies Mentioned: - Hoffmann-La Roche - Eli-lilly - Sanofi - Otsuka Holdings - Novartis - Amgen - Boston Biomedical - AROG Pharmaceuticals - ARIAD Pharmaceuticals - Roche - Merck - Eli Lilly - AB Science - Galena Biopharma - AstraZeneca - Taiho Oncology - Samumed - Ipsen Biopharmaceuticals - Eddingpharm - Tekmira Pharmaceuticals - Bristol-Myers Squibb - Gilead Sciences - ASLAN Pharmaceuticals - Five Prime - Array Biopharma - BIND Therapeutics - Boehringer Ingelheim - Daiichi-Sankyo - Bayer HealthCare - Celgene. Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Disease overview PART 06: Pipeline portfolio PART 07: Market landscape PART 08: Market segmentation by molecule type PART 09: Market segmentation by route of administration PART 10: Market segmentation by lines of chemotherapy PART 11: Geographical segmentation PART 12: Market drivers PART 13: Impact of drivers PART 14: Market challenges PART 15: Impact of drivers and challenges PART 16: Market trends PART 17: Vendor landscape PART 18: Key vendor analysis For more information visit http://www.researchandmarkets.com/research/dd...al_gastric
GILD: 81.68 (-1.69), MRK: 56.72 (-0.96), TKMR: 10.83 (+0.58), AMGN: 147.83 (-4.44), GALE: 2.07 (-0.08), LLY: 74.45 (+0.51), BIND: 0.40 (unch), BMY: 71.48 (-1.16), ARIA: 7.35 (-0.19), NVS: 78.41 (-2.26), CELGZ: 1.54 (+0.09)
Non-Hodgkin Lymphoma - Pipeline Review, H1 2015
M2 - Thu Sep 10, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njqxnc/nonhodgkin) has announced the addition of the "Non-Hodgkin Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 110 companies mentioned in this comprehensive report: - AB Science - AbbVie - BioAtla, - Biogenomics - Calimmune - Calithera Biosciences - Dicerna Pharmaceuticals - Eisai Co. - Eli Lilly and Company - F. Hoffmann-La Roche - Formula Pharmaceuticals - Galderma - Gamida Cell - Hetero Drugs - Hospira - iDD biotech - Immune Design - Johnson & Johnson - Juno Therapeutics - Kainos Medicine - Karyopharm Therapeutics - MedImmune - Merck & Co. - Nordic Nanovector - Novartis - OncoSec Medical - Onxeo - Pfizer - Pharma Mar - Richter Gedeon - Sanofi - Tekmira Pharmaceuticals - Vivia Biotech - Xenetic Biosciences - Zymeworks For more information, including full list of companies mentioned, please visit http://www.researchandmarkets.com/research/njqxnc/nonhodgkin
IMDZ: 8.07 (-0.23), DRNA: 3.09 (-0.20), TKMR: 10.83 (+0.58), LLY: 74.45 (+0.51), JNJ: 116.38 (-1.00), MRK: 56.72 (-0.96), CALA: 4.02 (-0.19), ONCS: 1.58 (-0.02), JUNO: 41.95 (-1.75), KPTI: 7.77 (-0.26), NVS: 78.41 (-2.26)
High Triglyceridemia - Pipeline Review, H2 2015
M2 - Tue Sep 08, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k6prfz/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - BASF SE - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Essentialis, Inc. - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Michigan Life Therapeutics, LLC - Novartis AG - Pharmena SA - Tekmira Pharmaceuticals Corp. - Thetis Pharmaceuticals LLC For more information visit http://www.researchandmarkets.com/research/k6prfz/high
AGN: 228.48 (-5.03), ACST: 1.50 (+0.04), ISIS: 57.56 (-0.28), AZN: 28.20 (-1.09), TKMR: 10.83 (+0.58), CBAY: 1.72 (-0.07), NVS: 78.41 (-2.26)
InMed Appoints Paul Brennan to the Board of Directors
Marketwired - Tue Aug 25, 4:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company"
(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Paul Brennan to the Company's Board of Directors. Mr. Brennan brings more than 25 years of experience in building, leading and advising top-performing pharmaceutical and biotechnology companies in Europe, Canada and the United States. ABUS: 3.45 (-0.09), TKMR: 10.83 (+0.58)
Arbutus Biopharma (NASDAQ: ABUS) Finalizes Corporate Name Change From Tekmira Pharmaceuticals
GlobeNewswire - Mon Aug 03, 4:45AM CDT
Arbutus Biopharma Corporation (NASDAQ:ABUS) today announced finalization of its corporate name change from Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR). Arbutus Biopharma ("Arbutus"
is an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV). Arbutus will begin trading under the new ticker symbol ABUS on the NASDAQ today. The company has also received a new CUSIP number (03879J100) for its common stock. ABUS: 3.45 (-0.09), TKMR: 10.83 (+0.58)
US Blood Cancer Drug Market & Pipeline Analysis 2015
M2 - Wed Jul 22, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp4cd3/us_blood_cancer) has announced the addition of the "US Blood Cancer Drug Market & Pipeline Analysis 2015" report to their offering. Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs. Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market. Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase. "US Blood Cancer Drug Market & Pipeline Analysis 2015" Report Highlights: - Blood Cancer Incidence & Prevalence - Blood Cancer Drug Market Overview - Blood Cancer Drug Market Dynamics - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs - Majority Drugs in Phase-I Clinical Trials: 128 Drugs - Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis - Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs Key Topics Covered: 1. US Blood Cancer Incidence & Prevalence 2. US Blood Cancer Drug Market Overview 3. US Blood Cancer Drug Market Dynamics 4. US Blood Cancer Drug Market Future Prospects 5. Mechanism of Blood Cancer Therapeutics 6. Leukemia Drug Clinical Pipeline by Company & Phase 7. Marketed Leukemia Drug Clinical Insight 8. Lymphoma Drug Clinical Pipeline by Company & Phase 9. Marketed Lymphoma Drug Clinical Insight 10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase 11. Marketed Multiple Myeloma Drug Clinical Insight 12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase 13. Marketed Multiple Blood Cancer Drug Clinical Insight 14. Competitive Landscape - ARIAD Pharmaceuticals - Actelion Pharmaceuticals - Amgen - Astellas Pharma - Baxter BioScience - Bayer HealthCare Pharmaceuticals Inc. - Biogen Idec - Bristol-Myers Squibb - CASI Pharmaceuticals - Celera Genomics Group - Celgene Corporation - Eisai Co Ltd - Genmab - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Millennium Pharmaceuticals - Nova Laboratories - Novartis - Onxeo SA - Onyx Pharmaceuticals - Otsuka Pharmaceutical - Pfizer - Roche - SRI International - Scripps Clinic - Seattle Genetics - Southern Research Institute - Tekmira Pharmaceuticals Corporation - Teva Pharmaceutical Industries - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/hp...ood_cancer
BIIB: 233.49 (-5.13), TKMR: 10.83 (+0.58), AMGN: 147.83 (-4.44), GSK: 40.97 (-1.59), BMY: 71.48 (-1.16), CASI: 1.21 (-0.02), JNJ: 116.37 (-1.01), GILD: 81.68 (-1.69), TEVA: 50.73 (-0.64), ARIA: 7.35 (-0.19), NVS: 78.41 (-2.26), CELGZ: 1.54 (+0.09)
Tekmira suspends work on Ebola drug, will change name
AP - Mon Jul 20, 3:21PM CDT
NEW YORK (AP) — One of the companies that had been studying a potential treatment for the Ebola virus said Monday it will suspend its research on Ebola drugs and change its name.
AGN: 228.48 (-5.03), INO: 9.42 (-0.43), TKMR: 10.83 (+0.58), GSK: 40.97 (-1.59), TKM.TO: 22.97 (+0.52)
The Single Greatest Mistake You Can Make When Investing in Biotech
Sean Williams, The Motley Fool - Motley Fool - Sun Jul 12, 1:02PM CDT
Source: Food and Drug Administration via Facebook Investing in the biotech sector since the Great Recession must be somewhat reminiscent of the pre-dot-com bubble for traders. These days it seems as if you threw a dart at the newspaper you could...
NVAX: 6.66 (-0.25), TKMR: 10.83 (+0.58)
Tekmira says Ebola drug unlikely to work in study
AP - Fri Jun 19, 5:02PM CDT
NEW YORK (AP) — Drugmaker Tekmira said Friday that an experimental treatment for a strain of Ebola will probably fail in a clinical trial.
TKMR: 10.83 (+0.58), TKM.TO: 22.97 (+0.52)
Tekmira Provides Update on TKM-Ebola-Guinea
GlobeNewswire - Fri Jun 19, 7:00AM CDT
Phase 2 clinical trial enrollment closed
TKMR: 10.83 (+0.58)
Tekmira to Present at JMP Securities Life Sciences Conference
GlobeNewswire - Thu Jun 18, 7:00AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced that Dr. Mark J. Murray, Tekmira's President and CEO, will present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 24, 2015 at 11.00am - 11.30am (PT) / 2.00 - 2.30pm (ET) in New York.
TKMR: 10.83 (+0.58)
Dementia drug developer Axovant climbs after $315M IPO
AP - Thu Jun 11, 6:32PM CDT
NEW YORK (AP) — Shares of Axovant Sciences nearly doubled in value after the dementia drug developer said its initial public offering raised $315 million, more than Axovant had expected.
TKMR: 10.83 (+0.58), GSK: 40.97 (-1.59), TKM.TO: 22.97 (+0.52)
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9bg7xn/adrenocortical) has announced the addition of the "Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Marathon Pharmaceuticals, LLC - Merck KGaA - Neotropix, Inc. - Orphagen Pharmaceuticals, Inc. - Pfizer Inc. - Tekmira Pharmaceuticals Corp. Drug Profiles - ATR-101 - avelumab - axitinib - MP-110 - NTX-010 - Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - TKM-PLK1 For more information visit http://www.researchandmarkets.com/research/9b...nocortical
PFE: 34.25 (-0.34), TKMR: 10.83 (+0.58)
